跳至主要内容
临床试验/NCT00570193
NCT00570193已完成1 期

Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study)

Mid-Atlantic Retina Consultations, Inc.0 个研究点目标入组 41 人开始时间: 2006年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
41
主要终点
Visual change

研究概览

简要总结

The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and as a tool for determining the need for retreatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

性别
All
接受健康志愿者

入选标准

  • All previously untreated CNV secondary to MD

排除标准

  • 未提供

研究组 & 干预措施

I

Experimental

Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)

干预措施: verteporfin (Visudyne) (Drug)

II

Experimental

Treatment with ranibizumab (Lucentis)

干预措施: ranibizumab (Lucentis) (Drug)

结局指标

主要结局

Visual change

时间窗: 18 months

次要结局

  • Frequency of treatment(18 months)

研究者

发起方
Mid-Atlantic Retina Consultations, Inc.
申办方类型
Other
责任方
Sponsor

相似试验